LGC Acquires Technopath Clinical Diagnostics to Strengthen Position in Clinical Diagnostics QC Market

LGC (Middlesex, UK) has acquired Technopath Clinical Diagnostics (Tipperary, Ireland), a developer and manufacturer of quality control (QC) solutions for clinical laboratories.

Technopath Clinical Diagnostics’ QC and software products are used by laboratories in over 120 countries globally. The acquisition augments LGC’s position in the clinical diagnostics QC market, complementing a wide breadth of existing manufacturing capabilities across calibration verification materials, molecular diagnostics and serology controls, clinical genomics reference materials and viral antigens.

“We are really excited to be bringing Technopath’s full-fledged chemistry and immunoassay controls into LGC,” said Euan O’Sullivan, President & Chief Operating Officer, LGC. “Their multi-constituent quality control products will dovetail perfectly with the calibration verification, molecular and serology product portfolios within our Clinical Diagnostics business unit. We look forward to combining Technopath’s and LGC’s expertise to deliver unrivalled solutions for our customers.”

“We are delighted to be joining LGC as an integral part of their fast-growing Clinical Diagnostics unit,” added Malcolm Bell, Chief Executive Officer, Technopath Clinical Diagnostics. “Technopath and LGC are an excellent fit as we share a purpose and mission, to support our customers by providing an expanded breadth of capability, geographic reach and scale. Our test consolidated multi analyte QC products allow end-customer labs to optimise their entire QC testing strategy while reducing waste and storage requirements and most importantly, reporting patient results with enhanced confidence and greater accuracy.”


Related Links:
LGC
Technopath Clinical Diagnostics